SproutNews logo

IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / January 31, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) (NASDAQ: SGEN) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired Seattle Genetics shares between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”), are encouraged to contact the firm prior to the March 17, 2017 lead plaintiff motion deadline.

If you purchased shares of Seattle Genetics, Inc. during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

The Complaint alleges that the Company announced the U.S. Food and Drug Administration enforced a clinical hold or partial clinical hold on the primary stage trials of the Seattle Genetics’ experimental cancer drug, vadastuximab talirine, to measure any potential threat of hepatotoxicity.

The Company noted that six acute myeloid leukemia patients had been diagnosed with liver toxicity, and that four had died.

When this news was revealed to the public, the value of Seattle Genetics stock dropped, causing investors harm.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.


Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474


SOURCE: Khang & Khang LLP

ReleaseID: 454008

Go Top